Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRALA targeted radiotherapy for AL amyloidosis
ISRCTN13400668Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jul 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of yttrium (90Y) besilesomab and indium-111 besilesomab in light-chain amyloidosis, sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Specific organ toxicity and Adverse event rate. Started Jul 2016; status: completed.
02
Drugs
yttrium (90Y) besilesomabindium-111 besilesomab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ISRCTN13400668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13400668.